Results 111 to 120 of about 143,566 (359)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +2 more sources

Supplementary Figure from A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy [PDF]

, 2023
Jing Yang, Shilin Zhao, Jing Wang, Quanhu Sheng, Qi Liu, Yu Shyr   +5 more
openalex   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

Blood Advances, 2017
: Classical Hodgkin lymphoma (cHL) is characterized by nearly universal genetic alterations in 9p24.1, resulting in constitutive expression of PD-1 ligands. This likely underlies the unique sensitivity of cHL to PD-1 blockade, with response rates of ∼70%
Reid W. Merryman, Philippe Armand, Kyle T. Wright, Scott J. Rodig   +3 more
doaj   +1 more source

Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. [PDF]

, 2020
There is a growing body of literature demonstrating the importance of T cell exhaustion in regulating and shaping immune responses to pathogens and cancer.
Canter, Robert J, Judge, Sean J, Murphy, William J   +2 more
core  

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Combination approaches with immune checkpoint blockade in cancer therapy

Frontiers in Oncology, 2016
In healthy individuals, immune checkpoint molecules prevent autoimmune responses and limit immune cell-mediated tissue damage. Tumors frequently exploit these molecules to evade eradication by the immune system.
Maarten Swart, Inge Verbrugge, Joost Beltman   +2 more
doaj   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Inducing Z-DNA overcomes immune checkpoint blockade resistance [PDF]

, 2022
Huipeng Jiao, Manolis Pasparakis
openalex   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source